Glaucoma News

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, L. Jay Katz, MD, chief medical officer at Glaukos, discusses phase 2 data for the company’s iDose device, which releases a continuous dose of travoprost.

Winter is the time of year for administration and paperwork. Taxes are due in the spring, and for those of us in private practice, it is the time to clean up and evaluate the business of our practice from the previous year.

ORLANDO — At Cataract Surgery: Telling It Like It Is, Michael D. Patterson, DO, discusses the use of endoscopic cyclophotocoagulation to lower IOP in patients with glaucoma who are undergoing cataract surgery.

SAN FRANCISCO — Joel S. Schuman, MD, FACS, discusses how regenerative medicine, including the use of insulin and stem cells, is making an impact in the treatment of glaucoma at the Glaucoma 360: New Horizons Forum.

ORLANDO — I. Paul Singh, MD, discusses the impact of resistance severity in addition to disease severity when deciding on a glaucoma treatment plan at Cataract Surgery: Telling It Like It Is.

SAN FRANCISCO — Alberto Gonzalez Garcia, MD, of olleyes discusses the company’s plan to bring a virtual reality glaucoma testing platform to clinicians at Glaucoma 360: New Horizons Forum.

SAN FRANCISCO — Michael Rowe, vice president of marketing for Eyenovia, discusses results of the MIST-1 trial of MicroStat, a fixed combination of phenylephrine 2.5% and tropicamide 1%, and demonstrates how Eyenovia’s OpteJet technology works at the Glaucoma 360: New Horizons Forum.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, George A. Cioffi, MD, discusses how the meeting’s marriage of industry professionals, venture capitalists and clinicians makes it unique.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, Michael Chiang, MD, discusses how telemedicine could assist in glaucoma management, as well as some of the challenges it faces in the near future.

The lateral decubitus posture affects IOP in the lower positioned eye, with further increase when it is maintained over 30 minutes, and in eyes with progressing glaucoma, according to a study.